D.Western Therapeutics Institute,Inc.is a biotechnology company that focuses on development of innovative new drags to serve patients worldwide.

DW-5LBT

DW-5LBT

Target disease Neuropathic pain after shingles
Development stage Filed NDA application in U.S.
Collaborative development company MEDRx Co., Ltd.
Overview DW-5LBT(MRX-5LBT) is a new type of lidocaine patch for the treatment of post-herpetic neuralgia that uses the ILTS® (lonic Liquid Transdermal System), an exclusive MEDRx technology incorporating the company’s ionic liquid expertise. DW-5LBT is being developed with the goal of targeting the market for Lidoderm®, a lidocaine patch.
In April 2020, we conducted collaborative development agreement with MEDRx. From now on, we will work with MEDRx to develop and commercialize the DW-5LBT(MRX-5LBT) in the United States.

Development Progress

2020 Apr. Conducted collaborative development agreement with MEDRx.
Aug. Filed NDA application in U.S.

 

PAGETOP
D.Western Therapeutics Institute, Inc.
1-18-11, Nishiki, Naka-ku,
Nagoyashi, Aichi 460-0003 Japan
TEL 81+52-218-8785
Copyright © D.Western Therapeutics Institute, Inc. All Rights Reserved.